Rezolute, Inc.

Equities

RZLT

US76200L3096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.86 ^USD	-19.21%		-15.88%	+188.16%

Apr. 18	JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	MT
Mar. 06	Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	CI

Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022

November 09, 2022 at 04:12 pm EST

Rezolute, Inc. reported earnings results for the first quarter ended September 30, 2022. For the first quarter, the company reported net loss was USD 9.83 million compared to USD 7.84 million a year ago.

Latest news about Rezolute, Inc.

JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	Apr. 18	MT
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	Mar. 06	CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 13	CI
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer	Jan. 24	CI
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	Jan. 23	CI
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	Dec. 13	CI
JMP Securities Adjusts Price Target on Rezolute to $7 From $8, Maintains Market Outperform Rating	Nov. 14	MT
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 13	CI
Rezolute Announces Further Evidence of RZ358?s Efficacy in Tumor-Mediated Hyperinsulinism	23-10-11	CI
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-14	CI
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-14	CI
Cantor Fitzgerald Adjusts Price Target on Rezolute to $5 From $7, Maintains Overweight Rating	23-06-28	MT
Rezolute to Start Late-Stage Study in Congenital Hyperinsulinism in Europe, Other Places	23-06-27	MT
Transcript : Rezolute, Inc. - Special Call	23-06-27
Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358	23-06-27	CI
Transcript : Rezolute, Inc. - Shareholder/Analyst Call	23-05-25
Canaccord Genuity Adjusts Price Target on Rezolute to $17 From $16, Maintains Buy Rating	23-05-19	MT
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Rezolute, Inc. Announces KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema	23-03-23	CI
Transcript : Rezolute, Inc. - Special Call	23-03-22
HC Wainwright Trims Price Target on Rezolute to $17 From $21, Maintains Buy Rating	23-02-14	MT
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10	CI
Rezolute Initiates Phase 2 Study of Treatment for Diabetic Macular Edema	22-12-15	MT
Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema	22-12-15	CI
Earnings Flash (RZLT) REZOLUTE Reports Q1 Loss $-0.19	22-11-09	MT

Chart Rezolute, Inc.

Duration

Period

More charts

Company Profile

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.54 USD

Average target price

9.667 USD

Spread / Average Target

+173.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REZOLUTE, INC.	+188.16%	142M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs